EXACT SCIENCES CORPEXAS

EXACT SCIENCES CORP (EXAS): trades by Congress and the executive branch

Every trade in EXACT SCIENCES CORP that a representative, a senator, the President or a senior official disclosed since 2019, newest report first. Each is read from the filer’s periodic transaction report and linked to it.

Latest report May 14, 2026 · Source · RSS feed

Trades disclosed
33since 2019
Members
6
Purchases / sales
15 / 18
Typical days to public
28median
Public after 45 days
2of 31 dated trades by Congress

Congress trade alerts · EXAS · free

Get an email when anyone in Congress trades EXACT SCIENCES CORP

Each new disclosure of a trade in the stock by a representative, a senator, the President or a senior official, with the filing.

An email when a member of Congress or the executive branch files a trade in EXAS, with the filing. Unsubscribe in one click.

Transactions

Every EXAS trade disclosed since 2019, newest report first
MemberAssetTypeAmountTrade dateLagPublicFiling
Donald TrumpPresidentEXASEXACT SCIENCES CORPBuy$1K–$15KMar 17, 202658dMay 14PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · Dependent childSell$1K–$15KMar 24, 202610dApr 3PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KMay 10, 202429dJun 8PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KFeb 1, 202435dMar 7PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · Dependent childSell$1K–$15KJan 2, 202440dFeb 11PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KNov 13, 202325dDec 8PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointBuy$1K–$15KOct 16, 202326dNov 11PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KSep 15, 202330dOct 15PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KMay 1, 202341dJun 11PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointBuy$1K–$15KJan 20, 202328dFeb 17PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · JointSell$1K–$15KJan 31, 202314dFeb 14PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · JointSell$50K–$100KDec 19, 202225dJan 13PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · Dependent childSell$1K–$15KMay 16, 202229dJun 14PDF
Eric LanderDirector, Office of Science and Technology PolicyEXASEXACT SCIENCES CORPSell$1K–$15KJul 30, 202140dSep 8PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KJun 3, 202142dJul 15PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · Dependent childBuy$1K–$15KMay 20, 202126dJun 15PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · Dependent childBuy$1K–$15KMay 20, 202126dJun 15PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · Dependent childBuy$1K–$15KMay 20, 202126dJun 15PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · JointBuy$50K–$100KMay 20, 202126dJun 15PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointBuy$1K–$15KNov 11, 202028dDec 9PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointBuy$1K–$15KOct 26, 202010dNov 5PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KSep 15, 202028dOct 13PDF
Kevin HernR-OKOK01EXASExact Sciences Corporation · JointBuy$1K–$15KJul 27, 202019dAug 15PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KJun 5, 202034dJul 9PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KJun 2, 202037dJul 9PDF
Donna ShalalaD-FLFL27EXASExact Sciences CorporationSell$1K–$15KJun 24, 2019308dApr 27PDF
Donna ShalalaD-FLFL27EXASExact Sciences CorporationBuy$1K–$15KJun 19, 2019313dApr 27PDF
Gilbert CisnerosD-CACA39EXASExact Sciences CorporationBuy$1K–$15KMar 16, 202031dApr 16PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointBuy$1K–$15KJan 22, 202019dFeb 10PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointBuy$1K–$15KJan 10, 202031dFeb 10PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointSell$1K–$15KDec 10, 201927dJan 6PDF
Gilbert CisnerosD-CACA39EXASExact Sciences CorporationSell$1K–$15KSep 16, 201930dOct 16PDF
Josh GottheimerD-NJNJ05EXASExact Sciences Corporation · JointBuy$1K–$15KMay 10, 201936dJun 15PDF

Members who traded EXAS

MemberTradesBuysSellsLast tradedLatest report
Josh GottheimerD-NJNJ0517710May 10, 2024Jun 8, 2024
Kevin HernR-OKOK011055Mar 24, 2026Apr 3, 2026
Donna ShalalaD-FLFL27211Jun 24, 2019Apr 27, 2020
Gilbert CisnerosD-CACA39211Mar 16, 2020Apr 16, 2020
Donald TrumpPresident110Mar 17, 2026May 14, 2026
Eric LanderDirector, Office of Science and Technology Policy101Jul 30, 2021Sep 8, 2021

Source

Each trade is a line of a periodic transaction report filed under the STOCK Act, read from the report itself and linked to it. Three offices publish them, and all three are read here every hour: the House Clerk for representatives, the Senate Office of Public Records for senators, and the Office of Government Ethics for the President, the Vice President and Senate-confirmed officials (OGE Form 278-T). OGE links some officials’ reports and releases the rest on request; only linked reports are here.

The Act requires a report within 45 days of the trade; the lag counts the days from the trade to the day the report became public. Reports give each amount as a range. Amendments are marked and not counted as late; trades a later report withdrew are left out. The President’s reports and some House reports are scans of paper forms: a scanned value that does not read with certainty is shown as not read, never guessed, and the report is one click away. “Since” is the stock’s move from the trade date’s close to the latest daily close.

The same trades are in the OptimistFi MCP server’s get_congress_trades tool, by filer or by stock, for each chamber: connect it. Every House trade is free to download as CSV or JSON, and every trade here can be followed by RSS: the data.

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.